Counselors in Delafield, WI Accepting Medicare

25 Counselors found. Showing 21 - 25

Jennifer Worley Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 3195 Hillside Dr, Delafield, WI 53018 Phone: 262-646-9960    Fax: 262-646-9961

Czarina Encarnacion, LPC-IT Counselor Medicare: Not Enrolled in Medicare Practice Location: 383 Williamstowne Ste 101, Delafield, WI 53018 Phone: 262-337-9770    Fax: 262-337-9771

Mary Muhammad, LPC, CSAC Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 3195 Hillside Dr, Delafield, WI 53018 Phone: 262-646-9960    Fax: 262-646-9961

Heidi Lindsey Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 613b Milwaukee St, Delafield, WI 53018 Phone: 608-764-9806

Maureen Ann Pohle, L.P.C. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1444 E Devonshire Rd, Delafield, WI 53018 Phone: 262-894-3540    Fax: 262-303-4765

News Archive

XTIO2 presents XTI 360 ANTI-GERM SYSTEM to 83rd Academy Award-nominees

XTIO2 INC. (XTI) presented the 83rd Academy® Award-nominees with the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM, consisting of XTI 360™ Nanocoating and XTI™ Nano-Facemask. It is the world's most effective preventive measure and the best defense against germs transmitted via air and contact surfaces.

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis today announced it received the approval from the Taiwan Food and Drug Administration (TFDA) to start phase II clinical trial for its all-oral interferon (IFN)-free regimen to treat chronic hepatitis C (CHC).

Innovative miniscule gene transport system can cause breast cancer cells to self-destruct

Scientists at Queen's University Belfast have shown that they can deliver a gene directly into breast cancer cells causing them to self-destruct, using an innovative, miniscule gene transport system, according to research published today in the International Journal of Pharmaceutics.

Study: Prosthetic valve endocarditis associated with high one-year mortality rate

Prosthetic valve endocarditis (inflammation and infection involving the heart valves and lining of the heart chambers) remains associated with a high one-year mortality rate and early valve replacement does not appear to be associated with lower mortality compared with medical therapy according to a study by Tahaniyat Lalani, M.D., M.H.S., of the Naval Medical Center, Portsmouth, Virginia, and colleagues.

Read more Medical News

› Verified 8 days ago

• 1
• 2(current)